The systolic blood pressure (BP) measurement protocol, based on the SPRINT trial conducted in 2015, is meant to enable better blood pressure readings through proper patient positioning and minimizing interruptions.
“The SPRINT BP Protocol is the next step in helping caregivers standardize accurate and consistent BP measurements at the point of care — and Midmark is the first company to implement a SPRINT protocol with patient positioning guidelines in a vital signs acquisition device to help ensure the protocol is being followed,” said Kurt Forsthoefel, marketing director of medical products and services at Midmark.
“When the SPRINT BP Protocol was compared to routine BP measurements conducted in clinical settings, BP readings using the protocol were significantly lower than those readings from routinely performed measurement in a clinical setting. This outlines the importance of minimizing human variables that directly impact proper measurement, reducing hypertension misdiagnoses, reducing costs associated with obtaining multiple manual readings and ultimately, providing better patient care,” Forsthoefel said in a March 1 news release.
Medtech giant Henry Schein counts Midmark among its manufacturing partners.